KIT receptor is expressed in more than 50% of early-stage malignant melanoma: A retrospective study of 261 patients

Melanoma Research

Volumn 15, Issue 4, 2005, Pages 251-256

  Janku, Filip ^a   Novotny, Jan ^a   Julis, Ivan ^b   Julisova, Ivana ^b   Pecen, Ladislav ^c   Tomancova, Vera ^a   Kocmanova, Gabriela ^a   Krasna, Luboslava ^a   Krajsova, Ivana ^a   Stork, Jiri ^a   Petruzelka, Lubos ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b Biolab   (Czech Republic)

^c INSTITUTE OF MATHEMATICS   (Czech Republic)

Author keywords

KIT receptor; Malignant melanoma; Prognostic factor

Indexed keywords

STEM CELL FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PROTO-ONCOGENE PROTEINS C-KIT; RETROSPECTIVE STUDIES; SKIN NEOPLASMS;

EID: 23744513041     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200508000-00004     Document Type: Article

References (24)

1. Anonymous. Cancer incidence in the Czech Republic. Praha: UZIS; 2001.
2. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19:3635-3648.
3. Atkins MB, Lee S, Flaherty LE, Sosman JA, Sondak VK, Kirkwood JM, for the U.S. Melanoma Intergroup. A prospective randomized phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine (CVD), IL-2 and interferon alpha-2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): an ECOG-coordinated intergroup trial. Proc Am Soc Clin Oncol 2003; 22:Abstract 2847.
4. Danson S, Lorigan P, Arance A, Clamp A, Ranson M, Hodgetts J, et al. Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. J Clin Oncol 2003; 21:2551-2557.
5. Eton O, Legha SS, Moon TE, Buzaid AC, Papadopoulos NE, Plager C, et al. Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol 1998; 16:1103-1111.
6. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004; 351:998-1012.
7. Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor E, Hendrix M, et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 2000; 406:536-540.
8. Yarden Y, Kuang W-J, Yang-Feng T, Coussens L, Munemitsu S, Dull TJ, et al. Human protooncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 1987; 11:3341-3351.
9. Besmer P, Murphy JE, George PC, Qiu FH, Bergold PJ, Lederman L, et al. A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family. Nature 1986; 320:415-419.
10. Small D, Levenstein M, Kim E, Carow C, Amin S, Rockwell P, et al. STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34-human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc Natl Acad Sci USA 1991; 91:459-463.
11. Natali PG, Nicotra MR, Sures I, Santoro E, Bigotti A, Ullrich A. Expression of c-kit receptor in normal and transformed human nonlymphoid tissues. Cancer Res 1992; 52:6139-6143.
12. Miettinen M, Lasota J. Gastrointestinal stromal tumors: definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001; 438:1-12.
13. Tian Q, Frierson HFJ, Krystal GW, Moskaluk CA. Activating c-kit gene mutations in human germ cell tumors. Am J Pathol 1999; 154:1643-1647.
14. DiPaola RS, Kuczynski WI, Onodera K, Ratajczak MZ, Hijiya N, Moore J. Evidence for a functional kit receptor in melanoma, breast, and lung carcinoma cells. Cancer Gene Ther 1997; 4:176-182.
15. Nyormoi O, Bar-Eli M. Transcriptional regulation of metastasis-related genes in human melanoma. Clin Exp Metastasis 2003; 20:251-263.
16. Montone KT, van Belle P, Elenitsas R, Elder DE. Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression. Mod Pathol 1997; 10:939-944.
17. Balch CM, Buzaid AC, Atkins MB, Cascinelli N, Coit DG, Fleming ID, et al. A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer 2000; 88:1484-1491.
18. Verweij J, van Oosterom A, Blay JY, Judson I, Rodenhuis S, van der Graaf W, et al. Imatinib mesylate (STI-571 Glivec Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 2003; 39:2006-2011.
19. Potti A, Hille RC, Koch M. Immunohistochemical determination of HER-2/neu overexpression in malignant melanoma reveals no prognostic value, while c-Kit (CD 117) overexpression exhibits potential therapeutic implications. J Carcinogenesis 2003; 2:8.
20. Ohashi A, Funasaka Y, Ueda M, Ichihashi M. c-KIT expression in cutaneous malignant melanoma and benign melanocytic naevi. Melanoma Res 1996; 6:25-30.
21. Funasaka Y, Boulton T, Cobb M, Yarden Y, Fan B, Lyman SD, et al. c-Kit kinase induces a cascade of protein tyrosine phosphorylation in normal human melanocytes in response to mast cell growth factor and stimulated mitogen-activated protein kinase but is down-regulated in melanomas. Mol Biol Cell 1992; 3:97-209.
22. Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 2002; 20:1692-1703.
23. Heinrich MC, Corless CL, Blanke C, Demetri GD, Joensuu H, von Mehren M, et al. KIT mutational status predicts clinical response to STI 571 in patients with metastatic gastrointestinal stromal tumors (GISTs). Proc Am Soc Clin Oncol 2002; 21:2a.
24. Went PT, Dirnhofer S, Bundi M, Mirlacher M, Schraml P, Mangialaio S, et al. Prevalence of KIT expression in human tumors. J Clin Oncol 2004; 22:4514-4522.